Immune Response News and Research

RSS

COVID-19 infection sera analysis against varying antigens of SARS-CoV-2 variants

In a new study, researchers assessed the sera from COVID-19 infected and vaccinated individuals against the receptor-binding domain in the spike protein of the SARS-CoV-2 wildtype virus and its variants.

13 Jan 2022

Low incidence strategy for control of COVID-19

In a study published in The Lancet Regional Health – Europe, researchers from the Institute for Advanced Studies in Vienna argued for the benefits of a low incidence strategy to control the disease.

13 Jan 2022

Nanovaccines and their immunomodulatory effect against human viruses

A review ]presented the primary progress of nanovaccines against the main viral illnesses.

13 Jan 2022

The unique T cell response elicited by SARS-CoV-2 during a primary immune response by infection and vaccination

The distinctive characteristics of the T cell response generated by SARS-CoV-2 infection and vaccination and the relationship to CCCoVs and VOC was explored in a review published in Frontiers in Medicine.

13 Jan 2022

Overall survival rate has nearly doubled for Ph+ ALL patients after hematopoietic stem cell transplant

For patients with acute lymphoblastic leukemia (ALL) carrying the Philadelphia chromosome and whose disease relapsed after allogeneic hematopoietic stem cell transplantation (HCT), the two-year overall survival rate has nearly doubled from the period between 2000 and 2004 to the period between 2015 and 2019.

13 Jan 2022

Lack of evidence cross-reactive adaptive immune response is mechanism underlying COVID vaccine-induced myocarditis

Recently, the researchers from the USA, in their study published in the journal EBioMedicine, have conducted a sequence identity comparison and 3D protein structure comparison between the SARS-CoV-2 spike protein-derived peptides/protein and myocarditis-associated antigens and have found no significant enrichment in the frequency of spike-derived peptides similar to myocarditis-associated antigens that could have resulted in adaptive autoimmune responses leading to myocarditis.

12 Jan 2022

Cellular and humoral response to SARS-CoV-2 in multiple sclerosis patients using disease-modifying therapies

Researchers examine the effects of disease-modifying therapies implemented for treating multiple sclerosis on the immune response to SARS-CoV-2 infection.

12 Jan 2022

The impact of Comirnaty vaccination on the levels of PEG specific antibodies

Researchers observe an increase in PEG antibodies following vaccination with the SARS-CoV-2 mRNA lipid nanoparticle vaccine.

12 Jan 2022

Skin-related side effects may be an indicator that the cancer medications are working

Immune checkpoint inhibitors, which strengthen the immune response against tumor cells, have become standard of care for many patients with advanced cancers; however, the medications can often cause side effects, most commonly affecting the skin.

12 Jan 2022

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

A new study, posted to the medRxiv* preprint server, has focussed on the development of intranasal prophylaxis against SARS-CoV-2 infection.

11 Jan 2022

New technique could allow more diseases to be safely treated by nanomedicine

Researchers at Penn Medicine have discovered a new, more effective method of preventing the body's own proteins from treating nanomedicines like foreign invaders, by covering the nanoparticles with a coating to suppress the immune response that dampens the therapy's effectiveness.

11 Jan 2022

Study opens up prospects for using virotherapy to treat central nervous system tumors

In a study conducted at the University of São Paulo's Human Genome and Stem Cell Research Center (HUG-CELL) in Brazil, serial systemic injections of zika virus into mice with brain tumors destroyed the cancer without causing neurological damage or injuring other organs, and increased the animals' survival rate.

11 Jan 2022

Third dose of mRNA COVID vaccine induces strong immunity in older adults

A new study describes the beneficial effects of a third dose of the COVID-19 mRNA vaccine in strengthening immunity among older adults.

11 Jan 2022

Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Preliminary findings from Penn Medicine in an ongoing first-in-human clinical trial examining the safety, tolerability and feasibility of chimeric antigen receptor macrophage (CAR-M) has helped to establish the viability of this innovative immunotherapy, which advances the trailblazing scientific discovery of CAR T cell therapy- also pioneered at Penn- for solid cancer tumors and offers a promising new strategy in the fight against cancer.

11 Jan 2022

Immune Response News and Research

COVID-19 infection sera analysis against varying antigens of SARS-CoV-2 variants

Low incidence strategy for control of COVID-19

Nanovaccines and their immunomodulatory effect against human viruses

The unique T cell response elicited by SARS-CoV-2 during a primary immune response by infection and vaccination

Overall survival rate has nearly doubled for Ph+ ALL patients after hematopoietic stem cell transplant

Lack of evidence cross-reactive adaptive immune response is mechanism underlying COVID vaccine-induced myocarditis

Cellular and humoral response to SARS-CoV-2 in multiple sclerosis patients using disease-modifying therapies

The impact of Comirnaty vaccination on the levels of PEG specific antibodies

Skin-related side effects may be an indicator that the cancer medications are working

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

New technique could allow more diseases to be safely treated by nanomedicine

Study opens up prospects for using virotherapy to treat central nervous system tumors

Third dose of mRNA COVID vaccine induces strong immunity in older adults

Phase 1 clinical trial shows the safety, feasibility of CAR-M cell therapy for solid tumors

Withdrawing steroid treatment found to boost SARS-CoV-2 vaccine-induced immunity in kidney transplant recipients

Unraveling the early host-immune response to SARS-CoV-2 in mild COVID-19 infections

Study finds T cell response mostly conserved against SARS-CoV-2 Omicron variant following infection or vaccination

Study finds heterologous vaccine booster evokes robust immunity to SARS-CoV-2 Omicron variant

Mapping peripheral blood glycoprotein profiles of COVID-19 patients

SARS-CoV-2 activates microglia in the brain

Understanding the DNA Damage Response in Innate Immunity eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News